Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04574830 · ClinicalTrials.gov registry record
Study to Evaluate Biomarkers and Clinical Manifestations in Individuals With Glycogen Storage Disease Type III (GSD III)
A clinical trial, sponsored by Ultragenyx Pharmaceutical.
- Completed
- Registry status
- 18
- Enrollment target
NCT04574830: Completed study, sponsored by Ultragenyx Pharmaceutical.
NCT04574830 is a clinical trial that has completed, run by Ultragenyx Pharmaceutical. The registered enrollment target is 18 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04574830 has completed, sponsored by Ultragenyx Pharmaceutical.
- COMPLETED
- Registry status
- 18 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate potential biomarkers of GSD III.
Interventions
- OTHER No Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2020-11-23 |
| Est. Completion | 2022-06-30 |
What the finished NCT04574830 record still lists
NCT04574830 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 18 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which No Intervention is the first listed.
NCT04574830 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04574830 about?
NCT04574830 is a clinical study titled "Study to Evaluate Biomarkers and Clinical Manifestations in Individuals With Glycogen Storage Disease Type III (GSD III)". The primary objective of this study is to evaluate potential biomarkers of GSD III.
What is the current status of trial NCT04574830?
This trial is currently completed. The enrollment target is 18 participants. The study started on 2020-11-23. Estimated completion is 2022-06-30.
What interventions are being tested in trial NCT04574830?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT04574830?
This trial is sponsored by Ultragenyx Pharmaceutical, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI